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Post-renal acute renal failure
TV Patel1, S Kumar2 and AK Singh1
1Renal Division, Brigham and Women’s Hospital, Harvard Medical School, Boston, Massachusetts, USA and 2Division of Urology,
Brigham and Women’s Hospital, Harvard Medical School, Boston, Massachusetts, USA
CASE PRESENTATION
A 54-year-old Hispanic man with type 2 diabetes mellitus
and hypertension was initially evaluated at another
institution for difficulty voiding urine. He was found to
have a serum creatinine of 7.1 mg/dl that had increased
from his baseline of 1.0 mg/dl 2 years earlier. Renal
ultrasound revealed bilateral hydronephrosis with
hydroureter. In addition, he had significant enlargement
of his prostate. Over the ensuing 4 months, he underwent
three transurethral resections of his prostate for persistent
symptoms. His serum creatinine plateaued at 3.8 mg/dl.
He was referred to our institution for further evaluation
and management of his persistent symptom of voiding
difficulty and elevated creatinine.
At our institution, a detailed history and physical
examination was performed. His International Prostate
Symptom Score (IPSS) was 35, suggesting severe lower
urinary tract symptoms.1 He denied poly- or oliguria,
dysuria, fever, chills, and change in weight or appetite.
His medications included NPH insulin and amlodipine.
He denied tobacco, alcohol, and occupational chemical
exposure, exposure to asbestos, tuberculosis, or use
of over-the-counter medications. His family history was
not significant. Physical examination revealed a well-
appearing man with blood pressure of 126/80 mm Hg,
body mass weight 34 kg/m2. Jugular venous pressure was
9 cm H2O, lungs were clear to auscultation, cardiovascular
exam revealed a displaced left ventricle apical impulse,
the abdomen was obese, non-tender with no palpable
kidneys, and prostate enlargement on digital rectal
exam. Examination of the testicles was unremarkable.
Extremities did not reveal edema or changes of chronic
venous stasis. Normal dorsalis pedis pulses were present
on palpation.
Renal ultrasound revealed mild bilateral hydronephrosis
and hydroureter. Urodynamic measurements showed no
evidence of outlet obstruction. A trial of indwelling urinary
catheter was without benefit. Magnetic resonance
imaging of the abdomen showed fibrosed soft tissue
in the retroperitoneum, narrowing of the inferior vena
cava and hydronephrosis consistent with retroperitoneal
fibrosis (Figure 1a). Serology revealed an elevated
acute-phase reactants 126 mm/h, auto-antibodies
1:160 (speckled), and a positive anti-ribonucleo protein
(anti-RNP) assay. Investigation for secondary causes was
undertaken. Extensive drug history did not reveal any
medications that could cause retroperitoneal fibrosis
(e.g., methysergide, ergot derivatives, hydralazine, or
b-blocker). There was no history of trauma, radiation, or
malignancy. Purified protein derivative test was negative.
Prostate-specific antigen was 1.1 mg/dl (within normal
limits). Therefore, the diagnosis of idiopathic
retroperitoneal fibrosis (IRF) was presumptively made.
DIAGNOSIS
Idiopathic retroperitoneal fibrosis.
CLINICAL COURSE
After counseling the patient, steroids were administered
(prednisone 60 mg/day) and bilateral ureteral stents (7 French
24 cm double J-stents) were placed (Figure 1b). How-
ever, there was no improvement in the patient’s symptoms
or serum creatinine (3.4 mg/dl) after 3 months of inter-
vention. The patient had worsening hyperglycemia, hyper-
tension, and obesity, possibly due to high-dose steroid
therapy. Over this period, he also developed lower extremity
edema possibly due to progressive venous and lymphatic
compression. Given the poor response to conservative
medical therapy over the 7 months since presentation to
our institution, steroid therapy was stopped and the patient
underwent laparotomy with ureterolysis, lateralization, and
omental wrapping of the ureters. The intraoperative images
are shown in Figure 2.
Postoperatively, serum creatinine improved to 1.7 mg/dl at
3 months after surgery. Six years after surgery, the patient
remains symptom-free without immunosuppressive medica-
tions. The IPSS has improved to 10, suggesting mild lower
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urinary tract symptoms. His serum creatinine is 2.0 mg/dl
and elevated acute-phase reactants (ESR) 31 mm/h. Magnetic
resonance imaging (MRI) of the abdomen and pelvis with
gadolinium showed stable retroperitoneal fibrosis without
hydronephrosis or hydroureter after 6 years of follow-up care.
PATHOLOGY
Examination of the surgical biopsy specimen revealed dense
fibrous tissue with foci of chronic inflammation, consistent
with retroperitoneal fibrosis. No granulomatous disease or
neoplastic cells were identified (Figure 3).
DISCUSSION
The most common cause of post-renal acute renal failure
(ARF) in men is benign prostatic hyperplasia. When treating
patients with post-renal ARF, failure of therapy for the usual
causes should prompt an investigation for less common
etiologies. This case exemplifies the need for aggressively
pursuing other diagnoses, such as retroperitoneal fibrosis,
when there is suboptimal response to the initial management
strategy.
The first description of IRF dates back to 1905 when
Albarran described a case in the French literature. However,
in 1948, the disease became known as Ormond’s disease
because Ormond2 was the first to publish two cases of IRF in
the English literature. IRF is a rare clinical entity charac-
terized by the presence of chronic inflammation and marked
fibrosis of the retroperitoneal tissue. The idiopathic form
of the disease accounts for the more than two-thirds of
cases.3 A case–control study from Finland reported an
incidence of 0.1 per 100 000 person-years and a prevalence
of 1.38 per 100 000 people in 2004. Men are affected twice as
often as women; the mean age of presentation is 50 years, and
there is no evidence of familial, ethnic, or geographic
predisposition.4
The pathogenesis of IRF is multifactorial. Genetic studies
have revealed linkage with HLA-DRB1*03, an allele linked
to various autoimmune diseases, including type 1 diabetes
mellitus, myasthenia gravis, and systemic lupus erythe-
matosus.5 Environmental factors may also play a role. For
instance, occupational exposure to asbestos increases the risk
of developing IRF.4
IRF has been classified as a form of chronic periaortitis, a
systemic inflammatory condition. Inflammatory abdominal
aneurysm and perianeurysmal retroperitoneal fibrosis are the
two other forms of periarotitis. Inflammatory abdominal
aneurysm is characterized by deposition of inflammatory
tissue around the abdominal aneurysm without causing
obstruction, whereas perianeurysmal retroperitoneal fibrosis
is marked by tissue around the aortic aneurysm causing
obstruction of surrounding structures. The hallmark feature
of chronic periaortitis is adventitial and periadventitial
inflammation.6 The local inflammatory reaction is believed
to result from oxidized low-density lipoprotein (LDL) and
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Figure 1 | Representative images of the patient. (a) Preoperative MRI T2-weighted image (coronal view). (b) CT scan of the abdomen after
placement of ureteral stents.
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ceroid (a lipoproteic polymer resulting from LDL oxidation
within macrophages). Recently, this theory has been vali-
dated by detecting increased immunoglobulin G (IgG)7 in
the proximate extracellular ceroid, T and B lymphocytes in
the media and markers of activation and proliferation in the
adventitia.8 Plasma cells bearing IgG4 have been implicated
in the pathogenesis, raising the possibility of a clonal B-cell
disorder.9 Moreover, patients with IRF often have ESR and
C-reactive protein (CRP) and positive auto-antibodies
(ANA). This evidence makes a compelling argument that
IRF is a manifestation of a systemic autoimmune disease.
Secondary causes of IRF,3 account for the remaining one-
third of the cases of retroperitoneal fibrosis, and have been
most commonly associated with ergot derivatives (methy-
sergide), dopamine agonists (methyldopa and peroglide),
antihypertensive medications (b-blockers and hydralazine),
and analgesics (acetylsalicyclic acid and phenacetin). Caus-
ality has not been firmly established with most of these drugs.
Certain infections, for example, tuberculosis, radiotherapy,
trauma, and major abdominal surgery have also been impli-
cated in development of retroperitoneal fibrosis. A number of
malignancies are known to cause an intense desmoplastic
response to retroperitoneal metastasis, particularly carcino-
mas of the prostate and colon. Carcinoids, Hodgkin’s and
non-Hodgkin’s lymphoma, and sarcomas have also been
associated with retroperitoneal fibrosis.
IRF is a diagnosis of exclusion. There are no standardized
diagnostic criteria. Imaging modalities are the non-invasive
investigations of choice when IRF is suspected. They are also
useful for following the disease. The presence of a soft tissue
mass encasing the abdominal aorta with possible involvement
of neighboring structures such as ureters and IVC, usually
suggests retroperitoneal fibrosis. ESR support the diagnosis.
Gross pathology of the idiopathic form shows thick, white,
hard retroperitoneal plaque, which surrounds the abdominal
aorta, IVC, and the ureters, usually between the origin of the
renal vessels and the bifurcation of the common iliac vessels.
The microscopic appearance of IRF is described as sclerotic
tissue infiltrated by mononuclear cells. Malignancy-induced
retroperitoneal fibrosis has irregular shape and may have
atypical localization, in contrast to the idiopathic disease.10
Local invasion of neoplastic cells may be seen within the
fibrous tissue. Presence of granulomas should suggest
underlying chronic infection (e.g., tuberculosis).
CLINICAL FEATURES
Clinical features of IRF include abdominal pain, backache,
and renal colic and non-specific constitutional symptoms of
low-grade fever, nausea, vomiting, and fatigue. Compression
of surrounding structures, lymphatics, and visceral blood
vessels may produce lower extremity edema, deep vein
thrombosis, varicocele, hydrocele, constipation, and small
bowel obstruction. Involvement of ureters is reported in
more than 80% of cases.10 At presentation, such involvement
is often bilateral, but in patients with an apparently unilateral
obstruction, contralateral disease can develop within a short
period. Hydronephrosis with ARF is rare as IRF is a gradual
process.11 Some patients present with varying degrees of renal
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Figure 2 | Intraoperative photographs. (a) Left ureter completely
mobilized ureter lifted by penrose drain. (b) Mobilized omentum – to
be used for ureteral wrap. (c) Completed omental wrap.
Figure 3 | Histopathology of IRF. Light Microscopy (hematoxyline
and eosin staining,  20) inflammatory infiltrate (arrows) and fibrosis
(arrowheads).
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insufficiency, probably caused by long-standing hydrone-
phrosis.12 As the clinical features are non-specific, there is
often a significant delay between onset of symptoms and
diagnosis. This frequently leads to the late complications of
chronic renal failure from post-renal ureteral obstruction.
DIAGNOSIS
In 80–100% of cases of IRF, acute-phase reactants are
elevated. Measurements of ESR and CRP may also be used
to monitor the disease. Normocytic, normochromic anemia
due to chronic inflammation and renal insufficiency may be
present. Azotemia may be present. Antinuclear antibodies in
low titers are present in 60% of patients, as was the case
in the patient described herein. Rheumatoid factor and ANA
against smooth muscle, double-stranded DNA may also be
positive. Their utility lies in detecting associated autoimmune
disorders. The presence of antibodies against thyroid
microsome and thyroglobulin usually indicates autoimmune
thyroiditis, which is the most frequent autoimmune disease
associated with retroperitoneal fibrosis.13 The frequency
of the association between IRF and other autoimmune
diseases is not known, mainly because the published reports
are limited to case series or case reports.
Imaging studies are essential for the diagnosis and
management of retroperitoneal fibrosis, and can sometimes
help to differentiate between the idiopathic and secondary
forms of the disease. Ultrasound is usually performed for
investigation for azotemia. Hypoechoic or isoechoic mass
may be visible suggestive of retroperitoneal fibrosis. Intra-
venous urography may reveal a non-diagnostic triad of
medial deviation, extrinsic compression of the ureters, and
hydronephrosis.14 Computed tomography (CT) and MRI
are the most reliable imaging modalities for the diagnosis of
IRF. On non-enhanced CT, IRF appears as a homogeneous
plaque, isodense with muscle, surrounding the lower
abdominal aorta and the iliac arteries, and encasing the
ureters and the inferior vena cava (IVC). Secondary IRF
owing to malignancy usually displaces the aorta anteriorly
and the ureters laterally. On MRI, IRF is hypointense in
T1-weighted images. In T2-weighted images, IRF intensity
is high in the early or active stages of the disease and low in
the late stages. Intensity is high owing to edema and hyper-
cellularity. The presence of an heterogeneous signal on
T2-weighted images suggests malignant retroperitoneal
fibrosis.13 Fluorodeoxyglucose-positron emission tomo-
graphy (FDG-PET) is not considered useful for the diagnosis
of the retroperitoneal fibrosis due to its low specificity. How-
ever, it can be considered a reliable means of assessing the
metabolic activity of the retroperitoneal mass. FDG-PET may
be helpful in detecting occult malignancy or infection.15
TREATMENT
The aims of the treatment for IRF are three-fold: to arrest the
progression of the disease, prevent recurrence, and to relieve
the obstruction of the ureters or other retroperitoneal
structures. Corticosteroids are the most commonly used
drugs and have greatly improved outcome. Steroids suppress
the synthesis of cytokines involved in the acute phase reaction,
reduce the inflammatory component and inhibit collagen
synthesis.15 They improve symptoms, reduce the size of
the retroperitoneal mass and help in resolution of obstruc-
tive complications. However, the dose, duration, and efficacy
of the steroids have not been well established. An initial
daily dose of prednisone 40–60 mg is administered. To
prevent relapse, treatment courses of up to 2 years are some-
times recommended. Treatment with Cyclophosphamide,
Azathioprine, Methotrexate, Cyclosporine, and Mycopheno-
late mofetil has been reported. No randomized studies have
compared the effectiveness of immunosuppressive drugs with
steroids. In a recent case series, tamoxifen showed improve-
ment in inflammatory markers and CT scan findings after
2.5 weeks. However, the major limitation of the study was
that there was no placebo arm.16 A conservative approach
with temporary placement of ureteral stents or nephrostomy
tubes followed by medical therapy is recommended, although
in refractory cases surgery is recommended.13 Open surgery
usually involves ureterolysis and intraperitoneal transposition
with omental wrapping of the entire length of the ureters to
relieve ureteral obstruction, to help prevent invasion by the
fibrotic tissue and to provide vascularity to the ureters.
Surgery does not prevent disease progression or recurrence,
and has no effect on systemic manifestations.11 Recently,
laproscopic ureterolysis has been reported.17
The prognosis for IRF is generally good, provided that a
timely diagnosis is made before the onset of complications.
Monitoring symptoms, ESR, CRP, and imaging is generally
recommended. Relapse rates are not known. Ureteral
obstruction is estimated to recur in up to half of the patients
who undergo surgery alone and in about 10% of those who
are treated with steroids and surgery.18 In the patient we
presented here, IRF was managed without long-term steroids
and thus, avoided the significant risks associated with long-
term corticosteroid therapy. This was particularly important
given the fact that our patient has a history of diabetes and
hypertension. In some instances, however, despite effective
medical treatment, residual retroperitoneal fibrotic tissue
is identified. Recently, a study using FDG-PET has shown
that in most patients with a stable clinical condition and
significantly decreased concentrations of acute-phase reac-
tants, the residual masses have very little or absent FDG
accumulation.19 This has suggested the presence of an
inactive, sclerotic disease that would be probably unrespon-
sive to further treatment.
CONCLUSION
This case illustrates the importance of persistent investigation
of post-renal ARF when the response to initial treatment for
more common causes is suboptimal. A multidisciplinary
approach and close collaboration between nephrologists,
urologists, and rheumatologists is essential for the manage-
ment of IRF. Follow-up of these patients is critical to prevent
recurrence and to retard the progression of the disease.
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